Park Medi World: ₹350 target call after 10% jump Mar-27

Stock jumps as Emkay initiates coverage

Park Medi World shares jumped as much as 10% even as the broader market stayed weak, after Emkay Research initiated coverage on the hospital chain with a ‘Buy’ rating. Emkay set a target price of ₹350 for March 2027, indicating about 35% to 37% upside from prevailing levels mentioned in the reports. The move stood out on a day when overall sentiment was cautious, but hospital stocks continued to show relative strength. The stock was seen trading around ₹276 on the NSE and ₹275.80 on the BSE at about 3:07 pm in one update. It later closed at ₹278.25 a share on the BSE, according to the same set of report excerpts.

What Emkay highlighted on business quality

Emkay’s initiation note pointed to Park Medi World’s business model and asset efficiency as key positives. The brokerage also flagged expansion plans, including work on a strategy to expand into high-demand markets such as Uttar Pradesh. In its projection, Emkay expects the company’s income to grow at 24% annually and EBITDA to grow at 23% annually between FY26 and FY29. The target price of ₹350 is based on valuing the company at 21x March 2028E EBITDA, which Emkay said is in line with the sector average. The emphasis, as stated, was on a model that can scale while maintaining operating discipline.

Balance sheet: net cash and cash flow focus

A key part of the Emkay thesis was financial strength. The brokerage cited a net cash position of about ₹200 crore, along with better cash flow and working capital management. In hospital businesses, the balance sheet can matter as much as growth, because expansions and acquisitions often require significant capital. Emkay’s note, as shared in the text, links the net cash and cash management to the potential for sustained investment in capacity and new geographies. It also frames the stock’s re-rating potential around these financial metrics rather than a single quarter’s performance.

A second brokerage view: Choice’s ₹350 target

Separate commentary in the provided text also referenced Choice Broking maintaining a ‘buy’ rating with a revised target price of ₹350 per share. That report discussed capacity expansion and improved financial performance, including a 30% revenue increase (as stated). In the same snippet, Park Medi World was described as being up about 90% year-to-date (YTD) and potentially having another 20% upside to the ₹350 target. The stock’s recent momentum was also highlighted, with mentions of an 11% gain in a week and a 20.50% rise in a month.

Acquisition catalyst: ₹177 crore all-cash deal

Park Medi World also drew attention after announcing the acquisition of a 100% stake in The Medicity Hospital in an all-cash deal valued at around ₹177 crore. In the excerpts, this acquisition was linked to the company’s entry into Uttarakhand and expansion of its North India healthcare network. One headline in the provided text connected a fresh record high move to a “₹177-crore acquisition of VS Healthcare,” while the detailed synopsis described the acquisition as The Medicity Hospital, suggesting the transaction involves the same asset referenced in multiple ways. Following this announcement, the stock was reported to have touched ₹280.80, up 8.2% from a previous close of ₹259.45, in one of the cited market updates.

Where Park Medi World stands in North India

The company was described in the text as the second-largest private hospital chain in North India and the largest in Haryana by bed capacity. These positioning statements matter because hospital operating leverage often improves as networks expand within a region, and brand recognition can support higher occupancy and better case-mix. The newly listed company has been on investors’ radar since its listing in December 2025, with one excerpt stating it delivered about 80% returns since listing. These claims were presented alongside multiple brokerage reports, indicating heightened sell-side coverage for the stock after listing.

Hospital stocks outperforming in 2026

The broader sector context also supported interest in hospital names. The text notes that Indian hospital stocks have shown resilience and outperformance in 2026, supported by strong earnings, strategic expansion, and rising healthcare demand. According to the provided data, the Nifty Healthcare index gained 7% while the Nifty 50 declined 8.5% in 2026. Park Medi World was cited as a top gainer among newly listed names, with one data point showing a 96% surge year-to-date, based on data compiled by Ace Equity. Other hospital stocks mentioned as gainers include Krishna Institute of Medical Sciences (KIMS), Aster DM Healthcare, Yatharth Hospital, and Apollo Hospitals Enterprise.

Other coverage: ₹320 target and technical commentary

Another excerpt referenced Choice Institutional Equities initiating coverage with a ‘buy’ rating and a target price of ₹320, implying 36% upside in that context. The brokerage note said it valued the company at 18x EV/EBITDA on FY28E. Separately, a market comment attributed to Anshul Jain, Head of Research at Lakshmishree, described the stock as making a strong structural move and “breaking out twice from its IPO base,” with a trend higher toward a “second base target of 255.” These references reflect a mix of valuation-based and price-action-based arguments in the market commentary included in the source text.

Key numbers at a glance

Why the story matters for investors

The immediate trigger for the rally was Emkay’s initiation and target price, but the broader story is about how quickly hospital operators can move from listing to active expansion and acquisition-led network building. The excerpts combine three levers that equity markets typically track for hospital chains: valuation benchmarks (EV/EBITDA multiples), balance sheet comfort (net cash), and visible growth plans (Uttar Pradesh expansion and the Uttarakhand entry through acquisition). At the same time, the reports show that target prices and YTD returns vary by source and time period, which is common during a strong momentum phase in a newly listed stock. Investors tracking the name will likely focus on how the ₹177 crore acquisition integrates into the North India network and whether the growth trajectory cited for FY26 to FY29 is reflected in execution updates and reported financial performance.

Conclusion

Park Medi World’s latest move came on the back of multiple ‘buy’ calls, with Emkay and Choice Broking both citing a ₹350 target, while another coverage note pegged a ₹320 target. Alongside those valuations, the company’s net cash position, working capital focus, and the ₹177 crore all-cash acquisition have been central to the recent narrative. With hospital stocks outperforming broader indices in 2026, the market is closely tracking how listed hospital networks expand capacity and geographies. The next set of investor cues will likely come from updates on integration of The Medicity Hospital and progress on expansion plans referenced in brokerage notes, including focus markets such as Uttar Pradesh.